Ravidasvir, the Glossary
Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by Pharco Pharmaceuticals) in clinical trials for chronic hepatitis C genotype 4.[1]
Table of Contents
6 relations: Clinical trial, Discovery and development of NS5A inhibitors, Hepatitis C, Sofosbuvir, The Guardian, WHO Model List of Essential Medicines.
- Experimental antiviral drugs
- Gilead Sciences
- NS5A inhibitors
Clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.
See Ravidasvir and Clinical trial
Discovery and development of NS5A inhibitors
Nonstructural protein 5A (NS5A) inhibitors are direct acting antiviral agents (DAAs) that target viral proteins, and their development was a culmination of increased understanding of the viral life cycle combined with advances in drug discovery technology. Ravidasvir and discovery and development of NS5A inhibitors are NS5A inhibitors.
See Ravidasvir and Discovery and development of NS5A inhibitors
Hepatitis C
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; it is a type of viral hepatitis.
See Ravidasvir and Hepatitis C
Sofosbuvir
Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used to treat hepatitis C. It is taken by mouth. Ravidasvir and Sofosbuvir are Gilead Sciences and World Health Organization essential medicines.
The Guardian
The Guardian is a British daily newspaper.
See Ravidasvir and The Guardian
WHO Model List of Essential Medicines
The WHO Model List of Essential Medicines (aka Essential Medicines List or EML), published by the World Health Organization (WHO), contains the medications considered to be most effective and safe to meet the most important needs in a health system. Ravidasvir and WHO Model List of Essential Medicines are World Health Organization essential medicines.
See Ravidasvir and WHO Model List of Essential Medicines
See also
Experimental antiviral drugs
- Aloxistatin
- Amdoxovir
- Apricitabine
- Asunaprevir
- BI 224436
- BIT225
- BMS-955176
- Beclabuvir
- Bemnifosbuvir
- Bepirovirsen
- Bevirimat
- Cenicriviroc
- ERDRP-0519
- FGI-103
- FGI-106
- Fabunan Antiviral Injection
- Favipiravir
- Galidesivir
- Odalasvir
- Racivir
- Radalbuvir
- Rafivirumab
- Ravidasvir
- Regavirumab
- Regdanvimab
- Remdesivir
- Riamilovir
- Rovafovir etalafenamide
- Samatasvir
- Sevirumab
- Stampidine
- Suvizumab
- Tabelecleucel
- Taribavirin
- Tuvirumab
- Vaniprevir
- Vicriviroc
- Vilobelimab
Gilead Sciences
- Adefovir
- Ambrisentan
- Amphotericin B
- Axicabtagene ciloleucel
- Brexucabtagene autoleucel
- Cidofovir
- Efavirenz/emtricitabine/tenofovir
- Elvitegravir/cobicistat/emtricitabine/tenofovir
- Emtricitabine
- Emtricitabine/rilpivirine/tenofovir
- Emtricitabine/tenofovir
- Gilead Sciences
- Immunomedics
- Kite Pharma
- Ledipasvir/sofosbuvir
- Lenacapavir
- Oseltamivir
- Pegaptanib
- Pharmasset
- Prostacyclin
- Ravidasvir
- Remdesivir
- Sofosbuvir
- Sofosbuvir/velpatasvir
- Tenofovir alafenamide
- Tenofovir disoproxil
- Velpatasvir
NS5A inhibitors
- Coblopasvir
- Daclatasvir
- Deleobuvir
- Discovery and development of NS5A inhibitors
- Elbasvir
- Elbasvir/grazoprevir
- Glecaprevir/pibrentasvir
- Ledipasvir
- Ledipasvir/sofosbuvir
- Odalasvir
- Ombitasvir
- Ombitasvir/paritaprevir/ritonavir
- Pibrentasvir
- Ravidasvir
- Samatasvir
- Sofosbuvir/daclatasvir
- Sofosbuvir/velpatasvir
- Sofosbuvir/velpatasvir/voxilaprevir
- Velpatasvir